



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/66, 37/02, 39/44	A1	(11) International Publication Number: WO 91/16071 (43) International Publication Date: 31 October 1991 (31.10.91)
(21) International Application Number: PCT/US91/02696 (22) International Filing Date: 19 April 1991 (19.04.91) (30) Priority data: 510,923 19 April 1990 (19.04.90) US (71) Applicant: RESEARCH DEVELOPMENT FOUNDATION [US/US]; 402 North Division Street, Carson City, NV 89703 (US). (72) Inventor: ROSENBLUM, Michael, G. ; 8810 North Rylander Circle, Houston, TX 77071 (US). (74) Agent: WEILER, James, F.; One Riverway, Suite 1560, Houston, TX 77056 (US).		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ANTIBODY CONJUGATES FOR TREATMENT OF NEOPLASTIC DISEASE (57) Abstract <p>Immunoconjugates of an antibody to a 240 kD melanoma tumor associated antigen were prepared. Cytotoxic immunoconjugates such as ZME-018 antibody conjugate are useful for treating proliferative cell diseases such as melanoma as well as other tumors which bear the ZME-018 antigen. Detectably labeled compositions for diagnosis of such diseases are also disclosed.</p>		

Best Available Copy

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

ANTIBODY CONJUGATES FOR TREATMENT OF NEOPLASTIC DISEASEField of the Invention

5 The present invention relates generally to the field of immunoconjugates and, more particularly, to the use of immunoconjugates in the treatment of cancer. The invention also relates to the treatment of melanoma with conjugates of monoclonal antibodies (MoAbs) and cytotoxic moieties such as gelonin, a ribosomal inhibiting protein, other plant-derived
10 cytotoxic moieties, or cytotoxic or cytostatic biological response modifiers.

Background of the Invention

The necessity for precisely targeting cancer therapy is critical since adequate tumor response is dependent upon
15 delivery and maintenance of intratumor therapeutic concentrations of drugs. Site-directed therapy has become a goal of several investigators utilizing monoclonal antibodies as specific carriers of therapeutic agents.

Cancer is one of the leading causes of mortality and
20 morbidity in the western world. There are many types of cancer, each with its own characteristics. However, cancers share at least one characteristic in common, they involve defects in the cellular growth regulatory process.

Melanoma, the most virulent of skin cancers, is a
25 highly metastatic disease affecting both sexes and is almost uniformly fatal within five years of diagnosis. Surgical removal of localized malignancies has proven effective only when the disease has not spread beyond the primary lesion. Once the disease has spread, the surgical procedures must be
30 supplemented with other more general procedures to eradicate

-2-

the diseased or malignant cells. Most of the commonly utilized supplementary procedures such as irradiation or chemotherapy are not localized to the tumor cells and, although they have a proportionally greater destructive effect on malignant cells, often affect normal cells to some extent.

Many tumors express antigens or antigenic determinants which are either expressed very weakly or not expressed at all by normal cells. Some tumor cells express antigens which are expressed by embryonic cell types but are not expressed by normal cells of a mature animal. These abnormally expressed antigens are known as tumor-associated antigens. These antigens are specific in that while a particular antigen may be expressed by more than one tumor, it is usually expressed by all or most cells of the particular tumors which express it. A tumor cell may express one or more than one tumor-associated antigen. These tumor-associated antigens may be expressed on the surface of the cell (cell surface antigen), may be secreted by the tumor cell (secreted antigens) or may remain inside the cell (intracellular antigen).

The presence of these tumor-associated antigens has been utilized to detect, diagnose and localize the tumor. In some cases the presence of the tumor-associated antigens on the tumor cells has allowed the targeting of specific drugs and other treatment means specifically to the tumor cells.

Antibodies are proteins normally produced by the immune system of an animal in response to foreign antigens or antigenic determinants. Antibodies bind to the specific antigen to which they are directed. For instance, antibodies to other melanoma antigens have been utilized to demonstrate specific tumor localization in man after systemic and intraperitoneal administration.

One method of targeting chemotherapeutic agents to tumor cells and to diminish their effects on normal cells has been made possible with the development of MoAbs directed against antigens on the tumor cells which do not

-3-

occur on normal cells. Monoclonal antibodies directed to specific antigens or antigenic determinants may be prepared in large quantities.

Antibodies may be labelled in order to allow their use for localization and treatment of malignant diseases. Such radiolabelled monoclonal antibodies to tumor cell surface antigens have been successfully utilized to image tumors in patients by external scintigraphy (Deland, Semin. Nucl. Med. 19(3): 158-65 (Review) (1989); Juhl, Hepatogastroenterology 36(1): 27-32 (Review), (1989)). Antibodies, coupled to drugs, may be used as a delivery system by which the drug is targeted to a specific tumor cell type against which the antibody is directed because of the antibodies' unique ability to localize at the tumor site after systemic administration. Antibodies may also be coupled to toxins and thus act as a delivery system to target the toxins directly to specific tumor cells.

The cytotoxic agents frequently utilized for antibody conjugates primarily fall into three classes of agents: toxins, radionuclides and chemotherapeutic agents. Antibody conjugates with each of these types of agents offer substantial promise as therapeutic agents but present some unique problems as well (Frankel, et al. Ann. Rev. Med. 37: 125-142 (1986); Reimann et al., J. Clin. Invest. 82(1): 129-138 (1988).). Immunoconjugates containing plant toxins also offer a unique advantage to other types of antibody conjugates because:

1. Doses of immunotoxins required for antitumor activity are, in general, much lower than that required for antibody-drug conjugates.

2. The conjugation of toxins to antibodies does not appear to affect antibody affinity.

Gelonin is a glycoprotein (M.W. approximately 29-30,000 Kd) purified from the seeds of Gelonium multiflorum. Gelonin belongs to a class of potent ribosomal-inactivating plant toxins. Other members of this class of ribosomal-inactivating plant toxins are the chains of abrin, ricin and modeccin. Gelonin, like abrin and ricin, inhibits

-4-

protein synthesis by damaging the 60S sub-unit of mammalian ribosomes. Although the A chain of ricin (RTA) has been popular for use in immunotoxins, gelonin appears to be more stable to chemical and physical treatment than RTA (Barbieri et al., Cancer Surv. 1: 489-520 (1982)). Furthermore, gelonin itself does not bind to cells and is, therefore, non-toxic (except in high concentrations) and is safe to manipulate in the laboratory. The inactivation of ribosomes is irreversible, does not appear to involve co-factors and occurs with an efficiency which suggests that gelonin acts enzymatically.

Numerous prior workers have suggested or reported linking cytotoxic agents to antibodies to make "immunotoxins." Of particular interest have been immunotoxins of monoclonal antibodies conjugated to the enzymatically active portions (A chains) of toxins of bacterial or plant origin such as ricin or abrin (Nevelle et al., Immunol. Rev., 62: 75-92 (1982); Ross et al., European J. Biochem. 104 (1980); Vitteta et al., Immunol. Rev. 62: 158-183 (1982); Ross et al., Cancer Res. 42: (1982) 457-464; Trowbridge and Domingo, Nature (Cond.) 294: 171-173 (1981)).

Gelonin and ricin are among the most active toxins which inhibit protein synthesis on a protein weight basis. Gelonin is 10 to 1000 times more active in inhibiting protein synthesis than ricin A chain. Peptides like ricin and abrin are composed of two chains, an A chain which is the toxic unit and a B chain which acts by binding to cells. Unlike ricin and abrin, gelonin is composed of a single chain, and, because it lacks a B chain for binding to cells, it is itself relatively non-toxic to intact cells (Stirpe, et al. J. Biol. Chem. 255: 6947-6953 (1980)). Mammalian cells apparently lack the ability to bind and/or to internalize the native gelonin molecule. Conjugates of gelonin with a tumor-targeting monoclonal antibody, such as the monoclonal antibody ZME directed to an antigen present on certain tumor cells such as melanoma cells, provide both a specific method for binding the gelonin to the cell and a route for internalization of the gelonin-antibody complex.

-5-

One of the advantages of using the toxin gelonin over using toxins such as ricin A chain is this reduced toxicity to normal tissues as compared to the ricin A chain.

5 Gelonin-coupled with a monoclonal antibody directed to an anti-tumor associated antigen is an active and selective immunotoxic agent for tumor therapy.

Previous studies have described a number of antibody-toxin conjugates containing gelonin (Lambert et al., J. Biol. Chem. 260: 12035-12038 (1985); Thorpe et al.,
10 Eur. J. Biochem 116: 447-454 (1981); Singh et al., J. Biol. Chem. 264: 3089-95 (1989); Scott et al., J. Natl. Cancer Inst. 79: 1163-72 (1987); Tedder et al., J. Immunol. 137(4): 1387-91 (1986)). Recently Ozawa, et al. (Int. J. Cancer 43: 152-157) have constructed a gelonin immunotoxin comprised of
15 antibody B467 which binds to the cellular receptor for epidermal growth factor (EGF). This B467-gelonin conjugate was highly cytotoxic for EGF receptor expressing cells but was non-cytotoxic for receptor-deficient cells. Sivam, et al. (Cancer Research 47: 3169-3173 (1987)) have made a
20 conjugate of the antimelanoma antibody 9.2.2.7 with gelonin and compared in vitro and in vivo cytotoxic activity with a 9.2.2.7 conjugate of abrin and ricin A chain. These studies demonstrated that gelonin conjugates show substantial cytotoxic effects selectively against antigen-positive cells
25 in vitro. In vivo experiments demonstrated that gelonin conjugates are not toxic up to 2 mg total antibody dose/mouse and that multiple I.V. administration of gelonin immunotoxin significantly retarded the growth of an established subcutaneous human tumor xenograft in nude mice.
30 Compared to conjugates with abrin and ricin, gelonin conjugates appeared to have similar potency, better selectively and tumor localization with more significant in vivo therapeutic properties.

Since the antibody to which the drug, toxin or
35 radioactive label is coupled binds only to tumor cells expressing a specific antigen, only the tumor cells are killed. Conversely, with radiation therapy, radiation from the radiolabelled compounds is not limited solely to the

-6-

tumor cells in which the radiation is taken up. For example, metabolic or enzymatic degradation of the antibody may release the radiolabel and allow it to distribute to other tissues such as kidneys or bone marrow, causing unacceptable radiation damage to these organs. Radiolabelled antibodies suffer from problems which limit or complicate their use as the therapeutic agents.

Summary of the Invention

The present invention provides immunoconjugates of an antibody (herein designated ZME-018) which recognizes the GP 240 antigen on melanoma cancer cells. One of the antibodies (225.28S) discussed by Wilson et al. (Wilson, et al., Int. J. Cancer 28: 293 (1981)) recognizes this melanoma membrane antigen. This antigen is identified therein by the designation GP 240. The antibody 225.28S which binds the GP 240 antigen has been designated and is further referred to herein as ZME-018. In one embodiment, the antibody is coupled with a toxin selected from the group consisting of gelonin, ricin A chain and abrin A chain. In another embodiment the ZME antibody may be coupled with a cytotoxic drug such as adriamycin or a biological response modifier such as a lymphokine or cytokine. In another embodiment the antibody may be labeled with a detectable label such as a radiolabel, a chemiluminescer, a fluorescer, or an enzyme label. The cytotoxic immunoconjugates are useful to treat and prevent recurrence of tumor-associated GP 240-bearing tumors by administration of these cytotoxic immunoconjugates to an individual in need of such treatment. The detectably labeled ZME immunoconjugates are useful for diagnosis and localization of tumors by techniques known to those in the art. These labelled immunoconjugates are also useful to assay for the presence of the GP 240 antigen in biological specimens and for localizing the tumor site in vivo by means known to those of skill in the art.

One of the objects of the present invention is to provide a cytotoxic composition which would specifically bind to and kill tumor cells. Particularly, it is an object of the present invention to provide a cytotoxic composition

-7-

which would specifically bind to and kill tumor cells which express the GP 240 antigen as described above. Antibody ZME-018 was prepared at Hybritech, Inc. using salt fractionation and DEAE chromatography and was judged
5 homogenous by SDS PAGE (Wilson et al., Int. J. Cancer 28: 293-300 (1981)). Another aspect of the invention concerns a method of killing human melanoma cells, or any other tumor cells expressing the ZME (GP 240) antigen, by contacting the cells with a cytocidally effective amount of an immunotoxin.

10 It is a further object of the present invention to provide such a composition which would be toxic to tumor cells but cause minimal injury to normal tissue.

Description of the Drawings

15 Figure 1 demonstrates the coupling and purification schema for ZME-gelolin.

Figure 2 demonstrates the purification of ZME- gelolin by S-300 gel permeation chromatography.

20 Figure 3 demonstrates the elution profile of the Cibachron-Blue sepharose column after the high-molecular weight material from S-300 chromatography was applied and eluted with a linear salt gradient (0-300 mM NaCl). Two protein peaks were demonstrated: a flow-through peak (fractions 14-20) and a bound peak eluted with high salt (fractions 44-75).

25 Figure 4 demonstrates the electrophoretic pattern of gelolin and ZME gelolin conjugate.

Figure 5 demonstrates comparative ELISA Assay data of ZME (open circles) and ZME gelolin (closed circles).

30 Figure 6 demonstrates the cytotoxicity of ZME- gelolin and free gelolin on log-phase AAB-527 cells after 72 hour exposure.

Figure 7 demonstrates the cytotoxicity of ZME- gelolin and free gelolin on log-phase AAB-527 cells.

35 Figure 8 demonstrates the cytotoxicity of ZME- gelolin on antigen positive target melanoma cells (AAB-527) and antigen negative T-24 cells in culture.

Figure 9 demonstrates the influence of free antibody on ZME-gelolin cytotoxicity.

-8-

Figure 10 demonstrates the effect of IFN- α , IFN- γ and TNF on ZME-gelonin cytotoxicity. Closed circles show the dose-response for ZME-gelonin alone. Open diamonds show the dose-response for ZME-gelonin plus IFN- γ . Open triangles show the dose-response for ZME-gelonin in the presence of a fixed amount of TNF- α . Closed circles with dotted lines show ZME-gelonin dose-response curve in the presence of a fixed amount of IFN- α .

Figure 11 demonstrates the effect of ZME-gelonin on antigen positive (A-375, closed circles) and antigen negative (CEM, open squares) cells in a human tumor stem cell assay.

Figure 12 demonstrates the cytotoxic effect of ZME-gelonin on stem cell survival of different lines obtained from fresh biopsy specimens of 4 different patients.

Figure 13 demonstrates the tissue distribution of ZME antibody and ZME-gelonin conjugate in nude mice bearing human melanoma xenografts.

Detailed Description of the Invention

As used herein the term "monoclonal antibody" means an antibody composition having a homogeneous antibody population. It is not intended to be limited as regards the source of the antibody or the manner in which it is made.

Melanoma cells express a 240 kD (GP 240) antigen on their cell surface. Antibodies to this antigen have been produced. Antibody ZME-018 (from Hybritech, Inc.) is a murine monoclonal antibody IgG_{2a} recognizing a 240 Kd glycoprotein present on most human melanoma cells.

Monoclonal antibodies of the IgG₁, IgG_{2a} and IgG_{2b} isotypes which recognize an epitope of this 240 kD antigen may be produced. This 240 Kd epitope of the ZME antigen will for the purpose of this invention will be designated the ZME epitope. Thus, all antibodies which recognize this ZME epitope are functionally equivalent.

These representative hybridoma cultures whose cells secrete antibody of the same idiootype, i.e., all recognize the ZME epitope, have been deposited at the American Type

-9-

Culture Collection of 12301 Parklawn Drive, Rockville, Maryland 20852 ("ATCC") and have been assigned the accession number _____.

5 These monoclonal antibodies may be made by methods known to those of skill in the art. The characterization of and procedure for making the hybridoma cell cultures which produce these antibodies is described in detail. (Wilson et al. Int. J. Cancer 28:293 (1981); Imai et al, Transplant Proc. 12:380-383 (1980)). Briefly, hybridomas were
10 constructed with the murine myeloma cell line Sp2/0-Ag-14 and splenocytes from mice immunized with the melanoma cell line M21 as described by Imai et al., ((1980) Transplant Proc. 12:380-383). The hybridomas secreting the monoclonal antibody (MoAb) 225.28S and 465.12 have been subcloned and
15 are propagated in vitro and in vivo. Both monoclonal antibodies are of the IgG_{2a} subclass and were purified from mouse ascites fluid by absorption/elution from protein A Sepharose 4B (Pharmacia, Piscataway, NJ, USA) prior to their use.

20 Hybridomas producing antibodies which reacted with human melanoma cells but not with normal human cells were further characterized. The antibodies produced by the ZME cell line and hybridoma producing functionally equivalent antibodies reacted with the ZME antigen on human melanoma
25 cells. They also reacted with 70 - 80% of randomly-obtained melanomas tested, and exhibited no reaction to various tissues as summarized on Table 1 in Example 4.

As used herein with respect to the exemplified murine monoclonal anti-human melanoma antibodies, the term
30 "functional equivalent" means a monoclonal antibody that:
(1) crossblocks an exemplified monoclonal antibody; (b) binds selectively to cells expressing the ZME antigen such as human melanoma cells; (c) has a G or M isotype; (d) binds to the ZME antigen as determined by immunoprecipitation or
35 sandwich immunoassay; and (e) when conjugated to gelonin, exhibits a tissue culture inhibitory dose (TCID) of at least 50% against at least one of the AAB-527, or A375 cell lines when used at a dose of 80-100 units per ml.

-10-

Antibody ZME was conjugated to gelonin using N- succinimidyl-3-(2-pyridyldithio)propionate (SPDP) or 2-iminothiolane (IT) as a coupling agent. The conjugates were tested against AAB-527 and A375 cells in a 72-hour tissue culture assay. The antibody conjugates exhibited acceptable antiproliferative activity (TCID 50% of less than 100 units ml) against both of these cell lines.

Further details of the characterization of the antibodies are provided in the examples below.

10 Immunochemicals

The immunochemical derivatives of this invention that are of prime importance are immunotoxins (conjugates of the ZME antibody and a cytotoxic moiety or a biological response modifier) and labelled (e.g., radiolabelled, enzyme-labelled, or fluorochrome-labelled) derivatives in which the label provides a means for identifying immune complexes that include the labeled antibody.

The cytotoxic moiety of the immunotoxin may be a cytotoxic drug or an enzymatically active toxin of bacterial or plant origin (gelonin), or an enzymatically active fragment ("A chain") of such a toxin. Enzymatically active toxins and fragments thereof are preferred and are exemplified by gelonin, diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolacca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, saponaria officinalis inhibitor, mitogellin, restrictocin, phenomycin, and enomycin. Most preferred is the conjugation with gelonin.

Biological response modifiers which may be coupled to the ZME antibody and used in the present invention include, but are not limited to, lymphokines and cytokines such as IL-1, IL-2, interferons (α , β , or γ) TNF, LT, TGF- β , and IL-6. These biological response modifiers have a variety of effects on tumor cells. Among these effects are increased tumor cell killing by direct action as well as increased

-11-

tumor cell killing by increased host defense mediated processes. Conjugation of antibody ZME to these biological response modifiers will allow selective localization within tumors and, hence, improved anti-proliferative effects while
5 suppressing non-specific effects leading to toxicity of non-target cells.

Cytotoxic drugs which are useful in the present invention include, but are not limited to, adriamycin (and derivatives thereof), cis-platinum complex (and derivatives
10 thereof), bleomycin and methotrexate (and derivatives thereof). These cytotoxic drugs are sometimes useful for clinical management of recurrent tumors and particularly melanoma, but their use is complicated by severe side effects and damage caused to non-target cells. Antibody ZME
15 may serve as a useful carrier of such drugs providing an efficient means of both delivery to the tumor and enhanced entry into the tumor cells themselves. In addition, specific antibody delivery of cytotoxic drugs to tumors will provide protection of sensitive sites such as the liver,
20 kidney and bone marrow from the deleterious action of the chemotherapeutic agents. Use of drugs conjugated to antibody ZME as a delivery system allows lower dosage of the drug itself, since all drug moieties are conjugated to antibodies which concentrate within the tumor.

25 Conjugates of the monoclonal antibody may be made using a variety of bifunctional protein coupling agents. Examples of such reagents are SPDP, IT, bifunctional derivatives of imidoesters such as dimethyl adipimidate. HCl, active esters such as disuccinimidyl suberate, aldehydes such as
30 glutaraldehyde, bis-azido compounds such as bis(p-azidobenzoyl) hexanediamine, bis-diazonium derivatives such as bis-(p-diazoniumbenzoyl)-ethylenediamine, diisocyanates such as tolylene 2,6-diisocyanate, and bis-active fluorine compounds such as a
35 1,5-difluoro-2,4-dinitrobenzene.

When used to kill human melanoma cells in vitro for therapeutic or for diagnostic purposes, the conjugates will typically be added to the cell culture medium at a

-12-

concentration of at least about 10 nM. The formulation and mode of administration for in vitro use are not critical. Aqueous formulations that are compatible with the culture or perfusion medium will normally be used.

5 Cytotoxic radiopharmaceuticals for diagnosing and treating tumors carrying the ZME antigen such as melanoma may be made by conjugating high linear energy transfer (LET) emitting isotopes to the antibodies. The term "cytotoxic moiety" as used herein is intended to include such isotopes.

10 The labels that are used in making labeled versions of the antibodies include moieties that may be detected directly, such as fluorochromes and radiolabels as well as moieties, such as enzymes, that must be reacted or derivatized to be detected. Examples of such labels are
15 ³²P, ¹²⁵I, ³H, ¹⁴C, fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferia, 2,3-dihydrophthalzainediones, horseradish peroxidase, alkaline phosphatase, lysozyme, and glucose-6-phosphate dehydrogenase. The antibodies may be tagged with such
20 labels by known methods. For instance, coupling agents such as aldehydes, carbodiimides, dimaleimide, imidates, succinimides, bis-diazotized benzadine and the like may be used to couple the antibodies with the above-described fluorescent, chemiluminescent, and enzyme labels.

25 The antibodies and labeled antibodies may be used in a variety of immunoimaging or immunoassay procedures to detect the presence of tumors expressing the ZME antigen such as melanoma in a patient or monitor the status of such cancer in a patient already diagnosed to have it. When used to
30 monitor the status of a cancer a quantitative immunoassay procedure may be used. Such monitoring assays are carried out periodically and the results compared to determine whether the patient's tumor burden has increased or decreased. Common assay techniques that may be used include
35 direct and indirect assays. Direct assays involve incubating a tissue sample or cells from the patient with a labeled antibody. If the sample ZME antigen bearing cells includes melanoma cells, the labeled antibody will bind to

-13-

those cells. After washing the tissue or cells to remove unbound labeled antibody, the tissue sample is read for the presence of labeled immune complexes.

For diagnostic use the antibodies will typically be distributed in kit form. These kits will typically comprise: the antibody in labeled form in suitable containers, reagents for the incubations and washings, and substrates or derivatizing agents depending on the nature of the label. Antigen ZME controls and instructions may also be included.

Administration of the immunotoxins of the present invention to an individual who has been diagnosed as having a tumor with the ZME antigenic determinant will allow targeting and concentration of the cytotoxic agent at the site where it is needed to kill the tumor cells. By so targeting the cytotoxic agents, non-specific toxicity to other organs, tissues and cells will be eliminated or decreased.

When used in vivo for therapy, the immunotoxins are administered to the patient in therapeutically effective amounts (i.e., amounts that eliminate or reduce the patient's tumor burden). They will normally be administered parenterally, preferably intravenously. The dose and dosage regimen will depend upon the nature of the cancer (primary or metastatic) and its population, the characteristics of the particular immunotoxin, e.g., its therapeutic index, the patient, and the patient's history. The amount of immunotoxin administered will typically be in the range of about 0.1 to about 10 mg/kg of patient weight.

For parenteral administration the immunotoxins will be formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable parenteral vehicle. Such vehicles are inherently nontoxic and nontherapeutic. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils and ethyl oleate may also be used. Liposomes may be used as carriers. The vehicle may contain minor amounts of

-14-

additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives. The immunotoxin will typically be formulated in such vehicles at concentrations of about 0.1 mg ml to 10 mg ml.

5 Gelonin toxin was purified from the seeds of gelonium multiflorum by the method of Stirpe, et al. Briefly, gelonin was extracted from the seeds by homogenization in buffered saline solution (pH 7.4). The supernatant was concentrated after dialysis against 5 mM sodium phosphate (pH 6.5) and the gelonin further purified by ion exchange chromatography as described in Example 1. The purity of the gelonin toxin was assessed by high pressure liquid chromatography (HPLC) and sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-Page). Gelonin toxin migrated as a single band with an approximate molecular weight of 29-30,000 daltons.

15 Gelonin toxin activity was measured as described in Example 2 by protein synthesis inhibition in a cell-free system.

20 Antibody ZME-018 modified with SPDP as described in Example 5 was conjugated with iminothiolane modified gelonin as described in Examples 3 and 6. The gelonin conjugated antibody was purified as described in Example 7 by column chromatography on a Sephadex G-75 column.

25 The toxicity of the gelonin-conjugated antibody was determined by protein synthesis inhibition and its antiproliferative activity was determined by in vitro and in vivo tests.

30 The following examples provide a detailed description of the preparation, characterization, and use of the immunotoxin monoclonal antibodies of this invention. These examples are not intended to limit the invention in any manner.

Example 1

Purification of Gelonin

35 Seeds of Gelonium multiflorum were shelled and the nuts ground in a homogenizer with eight volumes of 0.14 M NaCl containing 5 mM sodium phosphate (pH 7.4). The homogenate

-15-

was left overnight at 4°C. with continuous stirring, cooled on ice and centrifuged at 35,000 times g for 20 minutes at 0°C. The supernatant was removed, dialyzed against 5 mM sodium phosphate (pH 6.5) and concentrated using a pm10 filter. The sample was layered on a CM-52 ion-exchange column (20 x 1.5 cm) equilibrated with 5 mM sodium phosphate (pH 6.5). Material which bound to the ion exchange resin was eluted with 400 ml of 0 to 0.3 M linear NaCl gradient at a rate of 25 ml hour at 4°C. Five ml fractions were collected. The fractions were monitored at 280 nm in a spectrophotometer. The gelonin eluted in about fractions 55-70 and was the last major elution peak. Fractions 55-70 were pooled, dialyzed against double distilled water and concentrated by lyophilization. The purity and the molecular weight of each preparation was checked on high pressure liquid chromatography using a TSK 3000 gel permeation column with 50 mM sodium phosphate buffer, pH 7.4 and 15% sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-page). Gelonin migrated as a single band with an approximate molecular weight of 29-30,000 daltons.

Example 2

Assay of Gelonin Activity

The gelonin activity was monitored in a cell-free protein synthesis inhibition assay. The cell-free protein synthesis inhibition assay was performed by sequentially adding to 50 μ l rabbit reticulocyte lysate, thawed immediately before use, mixing after each addition, the following components: 0.5 ml of 0.2 M Tris HCl (pH 7.8), 8.9 ml of ethylene glycol, and 0.25 ml of 1 M HCl).

Twenty microliters of a salt-amino acid-energy mixture (SAEM) consisting of: 0.375 M KCl, 10 mM $\text{Mg}(\text{CH}_3\text{CO}_2)_2$, 15 mM glucose, 0.25-10 mM amino acids (excluding leucine), 5 mM ATP, 1 mM GTP, 50 mM Tris-HCl (pH 7.6), 10 μ l Creatinine phosphate-creatinine phosphokinase, 8 μ l ^{14}C leucine (Amersham, 348 mCi mmol), and adding 1.5 μ l of solutions containing varying concentrations of the gelonin mixture. The mixture was incubated for 60 minutes at 30°C.

-16-

¹⁴C-leucine incorporation was monitored in an aliquot of the mixture by precipitating synthesized protein on glass fiber filters, washing in 10% TCA and acetone, and monitoring the radioactivity in a Beta-counter using Aquasol scintillation fluid. Gelonin with a specific activity no lower than 4×10^9 U/mg was used for conjugation with the antibodies. A unit of gelonin activity is the amount of gelonin protein which causes 50% inhibition of incorporation of [¹⁴C] leucine into protein in the cell free assay.

Example 3

Modification of Gelonin With Iminoethiolane

Gelonin in phosphate buffered saline was concentrated to approximately 2 milligrams/ml in a Centricon 10 microconcentrator. Triethanolamine hydrochloride (TEA/HCl), pH 8.0 and EDTA were added to a final concentration of 60mM TEA/HCl and 1mM EDTA pH 8.0. 2-Iminoethiolane stock solution (20mM) was added to a final concentration of 1 mM and the sample was incubated for 90 minutes at 4°C. under a stream of nitrogen gas.

Excess iminoethiolane was removed by gel filtration on a column of Sephadex G-25 (1 x 24cm) pre-equilibrated with 5 mM bis-tris acetate buffer, pH 5.8 containing 50 mM NaCl and 1 mM EDTA. Fractions were analyzed for protein content in microtiter plates using the Bradford dye binding assay. Briefly, forty microliters of sample, 100 ul of phosphate buffered saline (PBS) and 40 ul of dye concentrate were added to each well. Absorbance at 600nm was read on a Dynatech Microelisa Autoreader. Gelonin elutes at the void volume (about fractions 14-20). These fractions are pooled and concentrated by use of a Centricon-10 microconcentrator.

Example 4

Preparation and Characterization of Monoclonal

Antibody to ZME Melanoma Antigen

Antibody-Secreting Hybridomas

One 8-week-old female BALB/c St mouse (SCRF Breeding Colony, La Jolla, Calif.) was injected intraperitoneally (i.p.) with 10^7 human melanoma M21 cells and boosted i.p. with 5×10^6 M21 cells 2 weeks later. One

-17-

50-week-old male NZB/B mouse (SCRF Breeding Colony) was primed with 5×10^6 BW5 melanoma cells and boosted with 5 injections of 5×10^6 BW5, M51, Colo 38, BW5 and M21 melanoma cells at monthly intervals. Three days after the booster injection, the mouse was sacrificed, and the spleen was removed, splenocytes were dissociated with a scalpel to make a cell suspension. The spleen cell suspension was treated with $0.17 \text{ } \partial \text{ NH}_4\text{Cl}$ in 0.01 M Tris , pH 7.2, for 10 min to lyse the red blood cells. Then, these splenocytes were fused with SP2/OAg14 cells as described by Geffer et al. ((1977) Somat. Cell Genet. 3:231.) with the following minor modifications: 5×10^7 spleen cells and 10^7 SP2/OAg14 cells were hybridized with 0.3 ml of 30% (v/v) polyethylene glycol 1000 (PEG) (Baker Chemical Co., Phillipsburg, N.J.) in MEM. After incubation with PEG the cells were washed, and cultured at a concentration of 2×10^6 cells/ml in D-MEM overnight. The next day, the cells were suspended in 40 ml HAT medium and pipetted into about 400 wells (0.1 ml/well) of microtiter plates (Costar #3596, Cambridge, Mass.) One drop (approximately 25ml) of HAT medium was added at weekly intervals. After 2-3 weeks, the hybridomas selected for further studies were cultured in D-MEM with 10% FBS. Hybridomas were expanded in tissue culture and were grown in the peritoneal cavity of BALB/c mice primed with 0.5 ml of Pristane (Pfaltz and Bauer, Inc., Stamford, Conn.). The spent culture medium and ascitic fluid were used as source of antibody.

Clones of the hybridoma were grown in vitro according to known tissue culture techniques such as is described by Cotten, et al., Eur. J. Immunol. 3: 136 (1973).

Hybridomas producing antibodies which reacted with human melanoma cells but not with normal human cells were further characterized.

As shown on Table 1, they did not react with most normal tissues tested. The antibodies produced by the ZME cell line and hybridomas-producing functionally equivalent antibodies reacted with the ZME antigen on human melanoma cells such as M-21.

-18-

TABLE 1NORMAL TISSUE REACTIVITY OF ANTIBODY ZME-018 (225.285)*

	<u>TISSUE</u>	<u>REACTIVITY**</u>
	Bladder	0/3
5	Brain Cortex	0/2
	Cartilage	0/2
	Colon	0/2
	Nipples	1/2
	Duodenum	0/1
10	Endometrium	0/1
	Kidney	0/2
	Liver	0/1
	Lung	0/4
	Lymph Node	0/3
15	Mammary Gland	0/3
	Ovary	0/1
	Pancreas	0/1
	Peripheral Blood	
	Lymphocytes	0/4
20	Peripheral Nerve	0/1
	Prostate	0/2
	Salivary Gland	0/3
	Skeletal Muscle	0/1
	Skin	0/5
25	Spleen	0/1
	Stomach	0/3
	Thyroid	0/2
	Tonsil	0/1
	Testes	0/5
30	*From P. Giacomini, et al. <u>Cancer Research</u> 44:1281-1287, 1984	
	**Number of samples antigen positive/ number samples tested.	

Example 5Modification of Monoclonal Antibody ZME-018 With SPDP

35 N-succinimidyl 3-(2-pyridyldithio) (propionate) (SPDP) in dimethylformamide was prepared as a stock solution of 3 mg ml in dry dimethylformamide. Since the crystalline SPDP can undergo hydrolysis, the actual concentration of

-15-

chemically reactive crosslinker was determined by spectrophotometric methods by analyzing the absorbance at 260 nm in a dual-beam spectrophotometer. The concentration of SPDP stock is calculated from the following equation:

$$\frac{\text{Change in absorbance (260nm)} \times (3.01)}{0.02 \times 10^3 \text{ ml mmol}} = \text{mmoles/ml/SPDP} \times 0.01$$

One milligram of monoclonal antibody ZME in 1.0 ml of phosphate buffered saline (PBS) was added to a glass tube. SPDP stock solution was slowly added at about a 5-fold molar excess to the tube (approximately 10 ul of stock solution), mixing constantly. The mixture was incubated for 30 minutes at room temperature, mixing every 5 minutes during the incubation period.

Excess unreacted SPDP was removed from the sample by gel filtration chromatography on a Sephdex G-25 column (1 x 24 cm) pre-equilibrated with 100 mM sodium phosphate buffer pH 7.0 containing 0.5 mM EDTA (Buffer A). Fractions (0.5 ml) were collected and analyzed for protein content using the Bradford dye binding assay (Bradford, Anal. Biochem. 72: 248-254 (1976)). Absorbance (600 nm) was monitored in a 96-well plate using a Bio-TEK Microplate autoreader. Antibody eluted at the void volume (fractions 14-20) and these fractions were pooled and kept at 4°C. The protein was concentrated in a Centricon-30 microcentrator. The Centricon retentate was washed with 100 mM sodium phosphate buffer, pH 7.0 containing EDTA (0.5 mM). The antibody was concentrated to a final volume of approximately 0.5-0.75 ml.

Example 6

Conjugation of SPDP-Modified Monoclonal Antibody ZME-018 With Iminoethiolane-modified Gelonin

One milligram of purified gelonin (2 mg/ml in PBS) prepared as described in Example 1 was modified with iminoethiolane as described in Example 3. Monoclonal antibody ZME modified as described in Example 4 was mixed with an equal weight of gelonin modified as in Example 3. This proportion corresponded to a 5-fold molar excess of gelonin as compared to antibody. The pH of the mixture was

-20-

adjusted to 7.0 by the addition of 0.05 M TEA/HCl buffer pH 8.0 and the mixture was incubated for 20 hours at 4°C under nitrogen. Iodoacetamide (0.1 M) was added to a final concentration of 2 mM to block any remaining free sulfhydryl groups and incubation was continued for an additional hour at about 25°C. The reaction mixture was stored at 4°C. until purification by gel filtration.

Example 7

Purification of Gelonin-Monoclonal Antibody

10

15A8 Complexes

Non-conjugated gelonin and low molecular weight products were removed from the reaction mixtures of Example 6 by gel filtration on a Sephadex S-300 column (1.6 x 31 cm) pre-equilibrated with PBS.

15

Reaction mixtures from Example 6 were concentrated to approximately 1 ml with a Centricon 30 microconcentrator before loading on the Sephadex column. The column was washed with PBS. One ml fractions were collected and 50 ul aliquots are analyzed for protein by the Bradford dye binding assay (Bradford, Anal. Biochem 72: 248 (1976)).

20

As shown on Figure 2, free- and gelonin-conjugated antibody eluted in the void volume (about fractions 28-40) while, unconjugated gelonin elutes at about fractions 45-65.

25

To remove unconjugated ZME-018, the high molecular peak (fraction 28-40) from the S-300 column was applied to an affinity chromatography column of Blue Sepharose CL-6B (1 x 24 cm) pre-equilibrated with 10 mM phosphate buffer (pH 7.2) containing 0.1 M NaCl. After sample loading, the column was washed with 30 ml of buffer to completely elute non-conjugated antibody. The column was eluted with a linear salt gradient of 0.1 to 2 M NaCl in 10 mM phosphate buffer pH 7.2. Protein content of the eluted fractions was determined by the Bradford dye-binding assay.

30

Figure 2 demonstrates the elution profile of the S- 300 column and demonstrates that gelonin can be separated from gelonin-antibody conjugate and unconjugated antibody, both of which coelute in the first peak (about fractions 28-40). This elution pattern was confirmed by electrophoresis of 50

35

-21-

ul aliquots on 5-20% gradient non-reducing SDS polyacrylamide gels as shown on Figure 4. The coupling mixture was loaded on lane 3. Bands for free gelonin (lane 2), free antibody (lane 1) and for one molecule of gelonin coupled per molecule of antibody and two molecules of gelonin coupled per antibody molecule are shown. The void volume peak of the S-300 column containing free antibody and antibody-gelonin conjugate was loaded on lane 4.

Non-conjugated antibody was removed from the gelonin conjugated antibody by affinity chromatography on a column (1 x 24 cm) of Blue Sepharose CL-6B pre-equilibrated with 10 mM phosphate buffer, pH 7.2 containing 0.1 M NaCl. After loading the S-300 eluate sample, the column was washed with 30 ml of the same buffer to completely elute non-conjugated antibody.

Gelonin-conjugated antibody bound to the column and was eluted with a linear salt gradient of 0.1 to 2 M NaCl in 10 mM phosphate buffer, pH 7.2. The antibody-gelonin complex eluted at approximately 0.7 M NaCl as shown on Figure 3 which depicts the elution profile of the Blue Sepharose column. Protein content of the eluted fractions was determined by the Bradford dye binding assay. The protein-containing fractions were pooled and the elution pattern confirmed by electrophoresis on a 5 to 20% gradient non-reducing polyacrylamide gel. The electrophoretic pattern of the ZME-gelonin complex is shown on Figure 4. The flow-through peak (fractions 14-20) contains only free antibody (Fig. 4, lane 5) while fractions 50-80, eluted with high salt, contain ZME-gelonin conjugate free of unconjugated gelonin or antibody (Fig. 4, lane 6). The final product contained ZME antibody coupled to 1, 2 and 3 gelonin molecules. Average gelonin content was 1.5 molecules per antibody molecule.

The rabbit reticulocyte in vitro translation system described in Example 2 was utilized to estimate the gelonin activity of the essentially pure gelonin-ZME antibody complex. One unit of activity in this assay was defined as the amount of protein required to provide 50% inhibition of

-22-

protein synthesis as compared to untreated controls. Utilizing this assay, the specific activity of both the native gelonin and the ZME-gelonin conjugate were determined to be 2×10^8 U/mg and 8.2×10^5 U/mg respectively. The essentially pure gelonin-ZME antibody is active in the reticulocyte lysate assay. A 1:1000 dilution of the original sample caused approximately a 50% inhibition of protein synthesis, i.e., a 50% reduction of the incorporation of ^{14}C -leucine into protein. Thus, the activity of the original preparation was 1000 U/ml.

EXAMPLE 8

Cell Culture Methods

ZME antigen-negative human bladder carcinoma (T-24) human cervical carcinoma or ZME antigen-positive human metastatic melanoma tumor cells A375M or AAB-527 were maintained in culture using minimal essential medium supplemented (MEM) with 10% heat-inactivated fetal bovine serum plus 100 mM non-essential amino-acids, 2mM L-glutamine, 1mM sodium pyruvate, vitamins and antibiotics. Cultured cells were routinely screened and found free of mycoplasma infection.

A. Cell Proliferation Assay

Cell lines were maintained in culture in complete medium at 37°C in a 5% CO_2 -humidified air incubator. For assays with combinations of TNF, immunotoxins, $\text{IFN}\alpha$, and $\text{IFN}\gamma$, cultures were washed, detached using versene, and resuspended in complete medium at a density of 25×10^3 cells/ml. Two hundred ml aliquots were dispensed into 96-well microtiter plates and the cells were then allowed to adhere. This results in a sparsely seeded population of cells. After 24 hours the media were replaced with media containing different concentration of either immunotoxins, toxins, TNF, $\text{IFN}\gamma$, or $\text{IFN}\alpha$. The cells were incubated for 72 hours and analyzed for relative cell proliferation by crystal violet staining.

B. Crystal Violet Staining

Cells were washed 3 times with PBS containing calcium and magnesium fixed and stained with 20% (v/v) methanol

-23-

containing 0.5% (v/v) crystal violet. Bound dye was eluted with 150 ul of Sorenson's citrate buffer (0.1M sodium citrate, pH 4.2-50% (v/v ethanol) for 1 hour at room temperature. The absorbance was measured at 600 nm using a Bio-Teck microplate reader. Relative cell proliferation (RCP) was calculated as follows:

$$\text{RCP} = \frac{\text{Mean Absorbance (Drug Treated)}}{\text{Mean Absorbance (Non-drug Treated)}} \times 100$$

C. Human Tumor Colony Assay

Tumor biopsy specimens were obtained from melanoma patients during clinically indicated biopsy procedures. Tumor cell suspensions were prepared aseptically (Leibovitz, et al., Int. J. Cell Cloning 1: 478-485 (1983)). Additionally, the A375P melanoma and the CEM leukemia cell lines from the American Type Culture collection (Rockville, MD) were also tested. Testing for the effects of ZME-gelonin on the fresh melanoma cell suspensions and cell lines was assessed in HTCA using standardized procedures for tumor cell plating in semisolid medium (agarose) in the presence of complete medium containing 10% fetal calf serum, each 0.5 ml culture plate containing 100,000 cells for fresh tumors and 10,000 cells for the cell lines (Hamburger, et al., Science 197: 461-463 (1977); Salmon, et al., N. Engl. J. Med. 298: 1321-1327 (1978); Salmon, et al., J. Clin. Oncol. 7: 1346-1350 (1989)). ZME-gelonin prepared as described above was tested by addition to the culture plates shortly after tumor cell plating. ZME-gelonin was added to triplicate plates at each of four concentrations 0.025 ng ml to 250 ng ml. In addition to untreated control plates, unconjugated ZME-18 monoclonal antibody and free gelonin were tested in parallel. Cell lines and tumor cell cultures were incubated for an average of 10 days at 37°C in 5% CO₂ in air in a humidified incubator, and colony formation evaluation with a viability stain (Shoemaker, et al., Cancer Res. 45: 2145-2153 (1985)) and an automated image analysis instrument optimized for colony counting (Salmon, et al., Int. J. Cell Cloning 2: 142-160 (1984)). Percent survival of ZME-018 treated cultures in relation to simultaneous

-24-

untreated controls were determined in the same experiments. Dose-response curves were then plotted graphically.

Example 9

Comparison of Binding of Gelonin-conjugated
and Unconjugated ZME Antibody to Target Cells

5 The ability of the gelonin-conjugated and unconjugated
ZME antibody to bind to target cells was assessed. The
binding of ZME-gelonin immunotoxin to antigen positive
(AAB-527 cells) or antigen negative (T-24 cells) was tested
10 by ELISA assay.

Fifty thousand target cells (AAB-527 cells) or
non-target (T-24 cells) were added to each well of
microtiter plate. The cells were dried on the plates
overnight at 37°C. The cells were then washed with three
15 changes of cold PBS and air dried overnight. The cell
surface antigenic determinants remain antigenically active
after this treatment.

After attachment of the cells, the plates were washed
with Washing Buffer (9.68 g Tris, 64.8 g sodium chloride, 16
20 ml Tween 20, 800 mg thimerasol in 8 l of double distilled
water). Antibody samples were diluted in Washing Buffer
containing 1% bovine serum albumin (w/v) (Diluting buffer).
Fifty microliters of various concentrations ranging from .02
to 50 ug/ml of either conjugated or unconjugated ZME
25 antibody were added to the wells. After incubation for 1
hour at 4°C, the supernatants are removed and the wells
washed twice with Washing Buffer.

Fifty microliters per well of horseradish peroxidase
conjugated goat anti-mouse IgG obtained from Bio-Rad and
30 diluted 1:1000 (v/v) (HPGAM) in Diluting buffer was added to
each well. The plates were incubated for 1 hour at 4°C and
the wells washed twice with Washing Buffer. After
incubation of the plates with 50 ul of Substrate Solution
(80 mM citrate phosphate (pH 5.0), 1 mM 2,2'AZINO-Bis
35 (3-ETHYL BENZ-THIAZOLINE-6-SULFONIC ACID) (ABTS) DIAMMONIUM
SALT (SIGMA CHEMICAL CO) and 4 ul of 30% hydrogen peroxide)
in the dark for 30 minutes at room temperature, 25 ul of 4 N

-25-

sulfuric acid was added to each well. The absorbance at 492 nm was determined on an Elisa reader.

As shown in Figure 5, both native ZME and the ZME gelonin conjugate bound well to target cells after 60 minute exposure. Surprisingly, the ZME-gelonin conjugate bound target cells better than did the native antibody. This increase was not due to modification of the antibody by SPDP since SPDP-modified ZME behaved identically to that of native ZME. The increase was also not due to binding of target cells to the gelonin portion of the molecule since pre-treatment of target cells with native gelonin had no effect on either antibody or immunotoxin binding.

Neither ZME nor ZME-gelonin bound to antigen negative T-24 cells as estimated by ELISA assay.

Example 10

Cytotoxicity of Gelonin and Gelonin-ZME Antibody Complex

Cytotoxicity studies of the ZME-gelonin conjugate were performed on antigen-positive cells after continuous (72 hour) exposure to the immunotoxin or native gelonin. As shown in Figure 6, when antigen-positive AAB-527 cells were exposed to approximately 0.1/nM ZME gelonin, 50% cell death was observed. When cells were exposed to native gelonin, a concentration of 100 nM gelonin was required to reduce the cell number to 50% of the untreated control.

Target cells were then treated with various concentrations of ZME-gelonin or gelonin alone on a unit basis as determined in Example 2. As shown in Figure 7, 50% cytotoxicity was obtained using 50 units/ml of ZME-gelonin conjugate while 1×10^7 units/ml of the free gelonin were required to achieve the same effect.

The effect of ZME-gelonin was determined against antigen-negative T-24 cells in log-phase culture. As shown in Figure 8, gelonin alone produced 50% cytotoxicity in AAB-S27 cells at a concentration of 100 ug/ml, similar to that found on AAB-S27 cells. ZME-gelonin produced 50% cytotoxicity in target T-24 cells at a concentration of 10 μ g/ml. However, the ZME-gelonin immunotoxin was not

-26-

cytotoxic against non-target T-24 cells even at the highest concentration tested.

5 In order to further demonstrate that the ZME gelonin cytotoxicity was mediated through the ZME cell surface antigen, a fixed dose of ZME-gelonin which achieves 80% cytotoxicity was added to target log phase melanoma cells in culture in the presence of free ZME antibody or an irrelevant antibody (15A8, an antibody that does not bind to melanoma cells). As shown on Figure 9, the presence of increasing amounts of ZME antibody suppressed the cytotoxicity of the ZME-gelonin conjugate while the 15A8 antibody had no effect. Thus, the cytotoxicity of the ZME-gelonin conjugate was directly mediated by the binding of the ZME antibody to ZME antigen on the target cell.

15 EXAMPLE 11

Modulation of ZME-gelonin cytotoxicity with
IFN α , IFN γ and TNF.

To demonstrate the effects of treatment with various biological response modifiers on immunotoxin cytotoxicity, log-phase melanoma cells were treated for 24 hours with fixed doses of IFN α (200 u/ml), IFN γ (20,000 u/ml) or rTNF- α (20,000 u/ml). These doses were previously determined to have minimal effect (approximately 20%) cytotoxic effect against these cells. The cells were then treated for 72 hours with various doses of ZME-gelonin. As shown in Figure 10, treatment with rIFN γ resulted in a 2-fold increase in sensitivity to the ZME-gelonin immunotoxin. However, pre-treatment with both rIFN α and TNF both resulted in a 2-log increase in sensitivity to the immunotoxin. Addition of fixed doses of rIFN α , rIFN γ or rTNF to antigen-positive cells resulted in augmented cytotoxicity of the ZME-gelonin toxin. Treatment with rTNF- α caused the greatest increase in immunotoxin cytotoxicity followed by rIFN α and rIFN γ .

35 Substantial augmentation of ZME-gelonin cytotoxic effect was observed with pre-treatment of rIFN α and rTNF but not with rIFN γ . While it has been observed that IFN α and IFN- γ can up-regulate some melanoma surface antigens such as

-27-

P-97, there was little effect of the agent on the high molecular weight antigen (GP 240) recognized by ZME (Murray, et al., Proc. Am. Assoc. Cancer Res. 27: 313 (1986); Greiner, et al., Cancer Res. 44: 3208-3214 (1984); Greiner, et al. Cancer Res. 46: 4984-4990 (1986); Groacomini, et al., J. Immunol. 133: 1649-1655 (1984); Imai, et al., J. Immunol. 127: 505-509 (1981); Murray, et al., J. Biol. Res. Mod. 7: 152-161 (1988).). Therefore, the mechanism of TNF α and IFN α induced augmentation of ZME-gelonin activity is not clear but could involve changes in the antibody internalization rate, changes in the cellular processing of the immunotoxin or a modulation of any one of several interferon-mediated enzymes.

Since only cells containing the ZME antigen on their surface were killed by the gelonin ZME immunotoxin, this immunotoxin is an efficient method to target and kill ZME tumor associated antigen containing cells while minimizing or preventing damage or injury to normal non-tumor associated antigen-bearing cells.

Example 12
Effect of ZME-Gelonin Immunotoxin
in Human Tumor Colony Assay (HTCA)

The activity of ZME-gelonin was also assessed using the human tumor colony assay against cells obtained from biopsy of four patients with melanoma.

In vitro cytotoxicity against human cells in culture was also assessed in the HTCA described in Example 8C. Various doses of ZME-gelonin immunotoxin were added to an antigen positive (A-375 melanoma) and antigen negative CEM cell lines. Survival of colonies was assessed 72 hours after addition. As shown in Figure 11, doses of immunotoxin between 0.25 and 2500 ng ml resulted in almost complete suppression of colony survival of the antigen-positive cell line (closed circle). ZME-018 and free gelonin alone or combined together were not cytotoxic. There was no effect against the antigen-negative line (CEM) even at the highest concentration of immunotoxin tested (open squares).

-28-

The effect of ZME-gelonin against 4 different fresh biopsy specimens is shown in Figure 12. Eighty to 90% reduction in survival of melanoma colony forming cells was found in two specimens at the highest immunotoxin dose tested (250 ng ml). One patient showed 50% inhibition of cell growth at this dose, while one patient showed no cytotoxicity of the immuno-conjugate. Only a modest (25%) reduction in colony number was noted with a third specimen. Growth enhancement was noted in the fourth sample at the highest immunotoxin dose. In addition, growth enhancement was observed in one specimen at low doses, while higher doses produced substantial cytotoxicity. As in the cell line experiments, addition of unconjugated ZME-018 and free gelonin were not cytotoxic at the doses tested.

While the HTSCA assay is not infallable, approximately 75% of clinically active antitumor agents are positive in this test system. Agents inactive in the HTSCA have thus far, proven inactive clinically. Therefore, activity of the ZME-gelonin conjugate in the HTSCA has a 75% probability of demonstrating positive clinical value.

Example 13

Tissue Distribution of ZME Antibody

The tissue distribution of ^{125}I labeled ZME antibody was compared to relevant immunotoxin (ZME-gelonin) and an irrelevant immunotoxin (15A8-gelonin). Each antibody or antibody-conjugate was administered intravenously in the tail vein to 5 nude mice bearing human melanoma xenografts. Each animal received 10mg of total protein labeled with 0.5 μCi of ^{125}I in a total volume of 100 μl of phosphate-buffered saline.

As shown in Figure 13, the irrelevant 15A8-gelonin conjugate did not localize specifically in tumor tissues (T/B ratio 0.5). In contrast, both the relevant ZME and ZME-gelonin conjugate demonstrated specific localization (T/B ratios of 2.0 and 1.5 respectively). There was no statistically significant difference in the uptake of ^{125}I into tumor after ZME or ZME-gelonin administration. One skilled in the art will readily appreciate that the present

-29-

invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The compounds, methods, procedures and techniques described herein are presently representative of the preferred embodiments, are intended to be exemplary, and are not intended as limitations on the scope of the present invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention and are defined by the scope of the appended claims.

What is claimed is:

-30-

Claims

1. A composition of matter comprising a conjugation of ZME antibody and a moiety selected from the group consisting of cytotoxic moieties and detectable labels.
- 5 2. The composition of claim 1 wherein said moiety is selected from the group consisting of a toxin, a cytocidal, a cytostatic drug, a biological response modifier and a detectable label.
- 10 3. The composition of claim 2, wherein said moiety is gelonin.
4. A method of treating proliferative cell diseases comprising administration of a cytocidally effect dose of the composition of claim 1 to an individual in need of said treatment.
- 15 5. A method of treating melanoma comprising administration of a gelonin coupled monoclonal antibody directed to ZME antigen to an individual in need of said treatment.
- 20 6. A method of preventing recurrence of melanoma tumors comprising administration of gelonin conjugated monoclonal antibody ZME to an individual diagnosed as having a tumor bearing ZME tumor associated antigen.
7. The method of any of claims 4-6, inclusive, wherein said individual is a human.
- 25 8. A method of enhancing the cytotoxic activity of immunotoxins comprising administration of a biological response modifier prior to the administration of an immunotoxin.

-31-

9. The method of claim 8 wherein said immunotoxin is selected from the group consisting of a gelonin conjugated monoclonal antibody, a ricin conjugated antibody and a TNF conjugated antibody.

5 10. The method of claim 9 wherein said antibody is selected from the group consisting of an antibody directed against a cell surface antigen of melanoma cells, a cell surface antigen of breast carcinoma cells, and a cell surface antigen of cervical cancer cells.


10 11. The method of claim 10 wherein said antibody is ZME-018.

12. The method of claim 8 wherein said biological response modifier is selected from the group consisting of IFNa and TNFa.

15 13. A method of enhancing the cytotoxic activity of immunotoxins comprising administration of a biological response modifier concurrently with the administration of an immunotoxin.



1 / 7

FIG. 1



SUBSTITUTE SHEET

2 / 7

**SUBSTITUTE SHEET**

3 / 7







FIG. 4





SUBSTITUTE SHEET



4 / 7

**SUBSTITUTE SHEET**

5 / 7



FIG. 8**FIG. 9****SUBSTITUTE SHEET**

6 / 7



SUBSTITUTE SHEET

7 / 7



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/02696

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): A61K 37/66, 37/02, 39/44 USCL.: 424/85.7, 85.1, 85.91																										
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched ⁷</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%;">Classification System</th> <th style="width: 75%;">Classification Symbols</th> </tr> <tr> <td style="text-align: center; vertical-align: top;">US</td> <td style="vertical-align: top;">424/85.7, 85.1, 85.91, 85.4.; 530/351, 391</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the extent that such Documents are Included in the Fields Searched ⁸</div> <p style="margin-top: 10px;">APS, CAS, BIOSIS</p>			Classification System	Classification Symbols	US	424/85.7, 85.1, 85.91, 85.4.; 530/351, 391																				
Classification System	Classification Symbols																									
US	424/85.7, 85.1, 85.91, 85.4.; 530/351, 391																									
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category ¹⁰</th> <th style="width: 60%;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">Y</td> <td>US, A, 4,590,071 (SCANNON ET AL) 20 MAY 1986. SEE COLUMNS 5,6 AND THE ABSTRACT.</td> <td style="text-align: center;">1-7</td> </tr> <tr> <td style="text-align: center;"><u>X</u> Y</td> <td>US, A, 4, 863,726 (STEVENS ET AL) 05 SEPTEMBER 1989, SEE COLUMNS 2,5,6.</td> <td style="text-align: center;"><u>8-10,13</u> 1-7,11,12</td> </tr> <tr> <td style="text-align: center;"><u>X</u> Y</td> <td>US, A, 4,894,227 (STEVENS ET AL) 16 JANUARY 1990, SEE COLUMNS 2,4,6.</td> <td style="text-align: center;"><u>8-10,13</u> 1-7,11,12</td> </tr> <tr> <td style="text-align: center;">Y</td> <td>US, A, 4,888,415 (LAMBERT ET AL) 19 DECEMBER 1989, SEE ABSTRACT AND COLUMNS 3,4.</td> <td style="text-align: center;">1-7</td> </tr> <tr> <td style="text-align: center;"><u>X</u> Y</td> <td>US, A, 4,894,225 (ZIMMERMAN) 16 JANUARY 1990, SEE COLUMNS 2-4</td> <td style="text-align: center;"><u>8-10,12,13</u> 1-7,11</td> </tr> <tr> <td style="text-align: center;">Y</td> <td>US, A, 4,894,443 (GREENFIELD ET AL) 16 JANUARY 1990, SEE COLUMN 7 AND CLAIM 3.</td> <td style="text-align: center;">1-7</td> </tr> <tr> <td style="text-align: center;">E, Y</td> <td>US, A, 5,017,371 (CUMMINS) 21 MAY 1991. SEE COLUMN 5.</td> <td style="text-align: center;">8-12</td> </tr> </tbody> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	Y	US, A, 4,590,071 (SCANNON ET AL) 20 MAY 1986. SEE COLUMNS 5,6 AND THE ABSTRACT.	1-7	<u>X</u> Y	US, A, 4, 863,726 (STEVENS ET AL) 05 SEPTEMBER 1989, SEE COLUMNS 2,5,6.	<u>8-10,13</u> 1-7,11,12	<u>X</u> Y	US, A, 4,894,227 (STEVENS ET AL) 16 JANUARY 1990, SEE COLUMNS 2,4,6.	<u>8-10,13</u> 1-7,11,12	Y	US, A, 4,888,415 (LAMBERT ET AL) 19 DECEMBER 1989, SEE ABSTRACT AND COLUMNS 3,4.	1-7	<u>X</u> Y	US, A, 4,894,225 (ZIMMERMAN) 16 JANUARY 1990, SEE COLUMNS 2-4	<u>8-10,12,13</u> 1-7,11	Y	US, A, 4,894,443 (GREENFIELD ET AL) 16 JANUARY 1990, SEE COLUMN 7 AND CLAIM 3.	1-7	E, Y	US, A, 5,017,371 (CUMMINS) 21 MAY 1991. SEE COLUMN 5.	8-12
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																								
Y	US, A, 4,590,071 (SCANNON ET AL) 20 MAY 1986. SEE COLUMNS 5,6 AND THE ABSTRACT.	1-7																								
<u>X</u> Y	US, A, 4, 863,726 (STEVENS ET AL) 05 SEPTEMBER 1989, SEE COLUMNS 2,5,6.	<u>8-10,13</u> 1-7,11,12																								
<u>X</u> Y	US, A, 4,894,227 (STEVENS ET AL) 16 JANUARY 1990, SEE COLUMNS 2,4,6.	<u>8-10,13</u> 1-7,11,12																								
Y	US, A, 4,888,415 (LAMBERT ET AL) 19 DECEMBER 1989, SEE ABSTRACT AND COLUMNS 3,4.	1-7																								
<u>X</u> Y	US, A, 4,894,225 (ZIMMERMAN) 16 JANUARY 1990, SEE COLUMNS 2-4	<u>8-10,12,13</u> 1-7,11																								
Y	US, A, 4,894,443 (GREENFIELD ET AL) 16 JANUARY 1990, SEE COLUMN 7 AND CLAIM 3.	1-7																								
E, Y	US, A, 5,017,371 (CUMMINS) 21 MAY 1991. SEE COLUMN 5.	8-12																								
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>																										
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top;"> Date of the Actual Completion of the International Search 15 July 1991 International Searching Authority ISA/US </td> <td style="width: 50%; vertical-align: top;"> Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em; font-weight: bold;">21 AUG 1991</div> Signature of Authorized Officer <div style="text-align: center;"> Kay K. Kim, Ph.D. </div> </td> </tr> </table>			Date of the Actual Completion of the International Search 15 July 1991 International Searching Authority ISA/US	Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em; font-weight: bold;">21 AUG 1991</div> Signature of Authorized Officer <div style="text-align: center;"> Kay K. Kim, Ph.D. </div>																						
Date of the Actual Completion of the International Search 15 July 1991 International Searching Authority ISA/US	Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em; font-weight: bold;">21 AUG 1991</div> Signature of Authorized Officer <div style="text-align: center;"> Kay K. Kim, Ph.D. </div>																									

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
<u>X</u> Y	J. NUCL. MED., VOLUME 28, ISSUED SEPTEMBER 1987, S. MING CHAN ET AL. "COMPARISON OF GALLIUM-67 VERSUS INDIUM-III MONOCLONAL ANTIBODY (96.5. ZME-018) IN DETECTION OF HUMAN MELANOMA IN ATHYMIC MICE", PAGES 1441-1446. SEE PAGE 1441.	<u>1,2</u> 3-13
<u>X</u> Y	BIOLOGICAL ABSTRACTS, VOLUME 84, NO. 10 ISSUED 1987, KIRKWOOD ET AL, "SCINTIGRAPHIC DETECTION OF METASTATIC MELANOMA USING INDIUM-III DTPA CONJUGATED ANTI-GP240 ANTIBODY (ZME-018)" SEE PAGE 628. COLUMN 1, ABSTRACT NO., 99695, J. CLIN. ONCOL. <u>5</u> (8): 1247-1255.	<u>1,2</u> 3-13
<u>X, P</u> Y	CANCER RESEARCH, VOLUME 50, NO. 19, ISSUED 01 OCTOBER 1990. PEARSON ET AL, "ENHANCED THERAPEUTIC EFFICACY AGAINST AN OVARIAN TUMOR XENOGRAFT OF IMMUNOTOXINS USED IN CONJUNCTION WITH RECOMBINANT α -INTERFERON", PAGES 6379-6388, SEE PAGE 6379.	<u>13</u> 1-12
<u>X</u> Y	CANCER RESEARCH, VOLUME 50, NO. 1, ISSUED 01 JANUARY 1990, YOKOTA ET AL, "SYNERGISTIC POTENTIATION OF <u>INVIVO</u> ANTITUMOR ACTIVITY OF ANTI-HUMAN T-LEUKEMIA IMMUNOTOXINS BY RECOMBINANT α -INTERFERON AND DAUNORUBICIN", PAGES 32-37, SEE PAGES 32-34.	<u>13</u> 1-12

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.